Literature DB >> 15385720

[Antibiotic resistance of Helicobacter pylori isolated from Korean patients in 2003].

Jung Mogg Kim1, Joo Sung Kim, Hyun Chae Jung, Nayoung Kim, In Sung Song.   

Abstract

BACKGROUND/AIMS: Development of antibiotic resistance is a significant clinical problem in the eradication of H. pylori. To select an appropriate regimen, systematic information on antibiotic resistance is mandatory. Thus, we investigated the distribution of minimal inhibitory concentration (MIC) and evaluated the antibiotic resistance of H. pylori isolates from Korean patients in 2003.
METHODS: The susceptibility of 65 isolates obtained in 2003 to amoxicillin, clarithromycin, metronidazole, tetracycline, azithromycin, and ciprofloxacin were determined by agar dilution method.
RESULTS: Resistance rates of H. pylori to amoxicillin, clarithromycin, metronidazole, tetracycline, azithromycin, and ciprofloxacin were 18.5%, 13.8%, 66.2%, 12.3%, 32.3%, and 33.8%, respectively. Multi-drug resistance rate of H. pylori was 47.7%. Especially, 6.2% of the H. pylori isolates were resistant to both amoxicillin and clarithromycin. In addition, resistance to amoxicillin and clarithromycin resulted in decreasing tendency of the eradication efficacy for H. pylori.
CONCLUSIONS: These results indicate that the antibiotics used for H. pylori eradication show high resistance rates in Korea. Furthermore, continuous surveillance of antibiotic susceptibilities should be needed and further increases in antibiotic resistance would require susceptibility testing before treatment to maximize the efficacy of H. pylori treatment.

Entities:  

Mesh:

Year:  2004        PMID: 15385720

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  7 in total

1.  Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection.

Authors:  Hyuk Soon Choi; Hoon Jai Chun; Sang Hoon Park; Bora Keum; Yeon Seok Seo; Yong Sik Kim; Yoon-Tae Jeen; Soon Ho Um; Hong Sik Lee; Chang Duck Kim; Ho Sang Ryu
Journal:  World J Gastroenterol       Date:  2012-05-21       Impact factor: 5.742

2.  Dual-priming oligonucleotide-based multiplex PCR using tissue samples in rapid urease test in the detection of Helicobacter pylori infection.

Authors:  Woo Chul Chung; Sung Hoon Jung; Jung Hwan Oh; Tae Ho Kim; Dae Young Cheung; Byung Wook Kim; Sung Soo Kim; Jin Il Kim; Eun Young Sin
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

3.  Antibiotic resistance in Helicobacter pylori strains and its effect on H. pylori eradication rates in a single center in Korea.

Authors:  Byoungrak An; Byung Soo Moon; Heejung Kim; Hyun Chul Lim; Yong Chan Lee; Gyusang Lee; Sa-Hyun Kim; Min Park; Jong Bae Kim
Journal:  Ann Lab Med       Date:  2013-10-17       Impact factor: 3.464

4.  Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change?

Authors:  Eun Jeong Gong; Sung-Cheol Yun; Hwoon-Yong Jung; Hyun Lim; Kwi-Sook Choi; Ji Yong Ahn; Jeong Hoon Lee; Do Hoon Kim; Kee Don Choi; Ho June Song; Gin Hyug Lee; Jin-Ho Kim
Journal:  J Korean Med Sci       Date:  2014-04-25       Impact factor: 2.153

5.  Antibiotic Resistance Patterns and Serotypes of Salmonella spp. Isolated at Jeollanam-do in Korea.

Authors:  Ki-Bok Yoon; Byung-Joon Song; Mi-Yeong Shin; Hyun-Cheol Lim; Yeon-Hee Yoon; Doo-Young Jeon; Hoon Ha; Soo-In Yang; Jung-Beom Kim
Journal:  Osong Public Health Res Perspect       Date:  2017-06-30

6.  Clarithromycin-based standard triple therapy can still be effective for Helicobacter pylori eradication in some parts of the Korea.

Authors:  Kyu-Hyun Yoon; Sung Woon Park; Sang Wook Lee; Beom Jin Kim; Jae Gyu Kim
Journal:  J Korean Med Sci       Date:  2014-09-02       Impact factor: 2.153

7.  Impact of previous metronidazole exposure on metronidazole-based second-line quadruple therapy for Helicobacter pylori infection.

Authors:  Gil Ho Lee; Kee Myung Lee; Sung Jae Shin; Joon Koo Kang; Choong-Kyun Noh; Jin Hong Kim; Sun Gyo Lim
Journal:  Korean J Intern Med       Date:  2020-07-31       Impact factor: 2.884

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.